H.R. 8857, Pharmaceutical Price Protection Carve-out. Quorum's AI analysis reads it as a net cost — and names who bears it.
H.R. 8857 · Net cost
What it does
This bill modifies Medicare's drug price negotiation program to give a new class of drugs called 'engineered cyclic peptides' an 11-year exclusion period before they can be subject to price negotiation, instead of the standard 7-year period. Engineered cyclic peptides are synthetic, lab-designed drugs composed of amino acids in a ring structure, developed using genetic screening, and taken orally or inhaled. The change applies immediately to future drug lists.
The analysis names pharmaceutical manufacturers — and 2 more groups — among the beneficiaries.
The cost
The 11-year exclusion period is 57% longer than the standard 7-year period, creating a significant window during which engineered cyclic peptides will command premium prices without Medicare negotiation pressure.
The analysis put a high warning level on this bill. Transparency scores 65%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Joseph Morelle. Cosponsored by August Pfluger, Josh Gottheimer and Thomas Kean.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.